Understanding Advanced Medullary Thyroid Cancer
This observational study aims to understand how advanced medullary thyroid cancer (MTC) develops and progresses. Researchers will collect information from a registry to learn about the natural course of MTC, including how it affects patients' experiences and quality of life. They will also look at how certain measurements and patient-reported information relate to the use and effectiveness of targeted therapies. This study is for adults diagnosed with MTC, particularly those with advanced disease (Stage III or IV). The goal is to gather information for up to four years to help improve how advanced MTC is managed. The current recruitment status is unclear.
- Study design
- This is an observational study planning to enroll 2030 participants. It is not a treatment study, but rather gathers information about the disease.
- What's involved
- Participants will undergo blood pressure measurements and complete questionnaires. This information will be collected for up to 4 years.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 4 years to track the natural history of MTC and their experiences.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Elizabeth G Grubbs · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Natural history of medullary thyroid cancer (MTC)Up to 4 years
Will describe the natural history of MTC using comprehensive battery of demographic, clinical, pathologic, and genotypic variables collected in existing multi-institutional patient registry.
- Patients' experience with the different phases of MTCUp to 4 years
Will characterize patients' experience with the different phases of MTC through a systematic evaluation of patient-reported outcomes (PROs).
- Association of selected biometric and patient-reported outcomesUp to 4 years
Will evaluate the association of selected biometric and patient-reported outcomes on adherence, change, and discontinuation of approved targeted therapies and drugs being tested within clinical trial.